Trial Profile
An Open-label, Sequential, Ascending, Repeated Dose-finding Study of Sarilumab, Administered with Subcutaneous (SC) Injection, in Children and Adolescents, Aged 2 to 17 Years, with Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA) Followed by an Extension Phase
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Apr 2024
Price :
$35
*
At a glance
- Drugs Sarilumab (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Pharmacokinetics
- Acronyms SKYPP
- Sponsors Sanofi
- 16 Feb 2024 Status changed from active, no longer recruiting to completed.
- 14 Feb 2024 This trial has been completed in Estonia (Global end date: 27 Dec 2023).
- 12 Feb 2024 This trial has been completed in the Netherlands (Global end date: 27 Dec 2023).